Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease.
about
Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysisCalcium and phosphate impact cardiovascular risk.Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis.FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy.Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart diseaseThe relation between serum phosphorus levels and clinical outcomes after acute myocardial infarctionFibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).Serum fibroblast growth factor-23 is associated with incident kidney disease.Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease.Fibroblast growth factor 23 and risk of incident stroke in community-living adultsFibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study.Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stonesFibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up studyFibroblast growth factor 23 and adverse clinical outcomes in chronic kidney diseaseEpidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study.Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease.Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study).Update on fibroblast growth factor 23 in chronic kidney disease.Relationship of serum fibroblast growth factor 23 with cardiovascular disease in older community-dwelling women.Treatment of phosphate retention: The earlier the better?Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study)Cardiovascular diseases in older patients with osteoporotic hip fracture: prevalence, disturbances in mineral and bone metabolism, and bidirectional linksFibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study.Associations among total and food additive phosphorus intake and carotid intima-media thickness--a cross-sectional study in a middle-aged population in Southern FinlandSingle FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients.Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study.Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: the Osteoporotic Fractures in Men (MrOS) Study.Fibroblast growth factor-23 and cardiovascular events in CKD.FGF-23 is a negative regulator of prenatal and postnatal erythropoiesisFibroblast growth factor 23 as a phosphotropic hormone and beyond.FGF-23: the rise of a novel cardiovascular risk marker in CKD.Phosphate is a vascular toxin.A short story of Klotho and FGF23: a deuce of dark side or the savior?Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study.Fibroblast growth factor 23 and heart failure: the plot thickens.Genetic Ablation of Fgf23 or Klotho Does not Modulate Experimental Heart Hypertrophy Induced by Pressure Overload.
P2860
Q26851216-64D989B7-152E-49F5-AE01-C6E7C564503AQ27687570-86F4E29E-86CF-457F-9838-6F14710E1A68Q33650866-D2730FE1-E6AC-49E3-BB68-45493A691B43Q34035797-07B8A636-5170-4143-9E80-F4FF9AD4710BQ34421217-6EF84F58-3058-488A-9B82-C1E981F6F267Q34625745-9E56938B-6FD4-4330-BA66-E2A5FCEC008DQ34669005-30A541EF-989E-4F9A-BE43-92F9C3BE5406Q34787817-586381D7-6B2B-4322-9E53-E148ACC7DEB7Q34981550-E3229501-05B5-4A31-B5CB-243B5B6903F0Q35019943-FA2B5599-333C-4B05-950A-99E5FE222DB6Q35021985-C42D2F60-4904-4D42-93FE-D3BC8D147938Q35153209-227D444E-5D40-481E-9C79-20CB83CF443BQ35278482-10784EFB-4BAF-4B26-A56B-EAD1CA9D5D0AQ35664606-3AA340A5-5DED-4EF8-B01C-A78E5AFA24B3Q35965337-832E09EB-AE6F-440C-9159-0B3CDF8F033DQ35997370-97A9C339-7A60-4A99-A23B-6DBF74F095E4Q36004493-3E05B5F8-47C1-4097-9774-52C3FDCF2AB2Q36015686-88C3733B-FF49-4FE8-8D6A-8CF05DCA317FQ36095111-0F174F9F-ADDA-45AF-B4AC-6E0211CB15A9Q36210285-1F66D982-49F5-4067-9CCE-CC3C98981619Q36364305-7233AF64-CE03-4F52-BCD1-BF160B12A718Q36466010-F106F56F-1139-40C0-9809-FF7BA95D5A20Q36536486-74680B1E-25A7-4307-A656-4CDBDC1BF131Q36648170-26F50314-1827-4704-8955-E0830F8C307DQ36739628-0A50739A-45D0-4793-9590-AB1BF89815A3Q37014354-24B952B1-9994-4B3A-96B1-5268C8DAA7BCQ37212400-825D961B-7C8B-4A82-A6AC-1DE4E25F611EQ37240698-D30711FE-356E-450C-A0E8-DCFDC59158C5Q37274273-65189D61-A8B6-4341-9CF0-62FD70BAEAFDQ37524119-E09F8286-4D88-4978-ABCE-5EF787224B15Q37683399-DEF25FC6-32A1-44DF-A135-3B9CF54FC948Q37913097-36956CCA-C75C-42AE-A2D0-06468C99ACFDQ38031216-78EF1DBE-0705-4A42-9346-9B30242A414AQ38060627-47491EB4-E025-4CFB-AC52-77B4D3547856Q38140738-5C07B74C-541A-4B2F-A44C-DE7FADA4A5A0Q38200883-9D2FDE2E-0432-460C-B400-2BCE9BEBCF11Q38609527-D9F0BB0F-8C0C-4572-8149-E14F025C974FQ39512523-D504951B-FF4B-4130-A68B-3E7FB8864444Q41091515-85528E4C-448F-416E-895F-91F968537FA0Q41200048-2018D6B8-CF1A-4ED6-8158-E52646539F71
P2860
Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@ast
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@en
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@nl
type
label
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@ast
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@en
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@nl
prefLabel
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@ast
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@en
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@nl
P2860
P1476
Plasma fibroblast growth facto ...... isk of coronary heart disease.
@en
P2093
Eric N Taylor
Gary C Curhan
P2860
P304
P356
10.1016/J.AHJ.2011.02.012
P407
P577
2011-05-01T00:00:00Z